ARS Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard E. Lowenthal
- Full Time Employees
- 155
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3525 Del Mar Heights Road San Diego CA United States of America 92130
- IPO Date
- Dec 4, 2020
- CIK
- 0001671858
- Website
- ars-pharma.com
- Similar Companies
- Business
- ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for severe allergic reactions, including anaphylaxis. Its primary product offering is neffy®, the first and only FDA-approved needle-free intranasal epinephrine spray designed for the emergency treatment of Type I allergic reactions in adults and children aged 4 years and older who weigh 33 pounds or more. Neffy® combines epinephrine with an absorption enhancer to provide rapid, injection-like absorption in a small, easy-to-use nasal spray, aiming to improve patient and caregiver confidence and prompt administration of epinephrine upon symptom onset. The company also conducts ongoing clinical trials for expanding the use of its intranasal epinephrine technology into additional indications such as chronic spontaneous urticaria. ARS Pharmaceuticals operates primarily in the United States and Europe, with headquarters in San Diego, California. Founded prior to its public listing and presently traded under the ticker SPRY on NASDAQ, the company targets at-risk patients with severe allergies, healthcare providers, and caregivers, offering a patient-friendly alternative to traditional injectable epinephrine products. Recent significant developments for ARS Pharmaceuticals include a strategic licensing agreement with ALK-Abelló A/S, under which ARS received an upfront payment of $145 million and is eligible for up to $320 million in regulatory and commercial milestone payments plus tiered royalties. This partnership assigns ALK responsibility for marketing, local market access, and sales of the neffy® product. In 2025, ARS launched a national direct-to-consumer advertising campaign to increase product awareness, contributing to a 180% increase in weekly prescription volumes of neffy® in the U.S. Furthermore, the company initiated a Phase 2b clinical trial for the treatment of acute flares in chronic spontaneous urticaria, enrolling patients across the U.S. and Europe, with topline data expected in early 2026. ARS has also secured broad commercial payer coverage, achieving 93% commercial coverage in the U.S. including 57% without prior authorization, substantially reducing administrative barriers for providers. Overall, ARS Pharmaceuticals delivers comprehensive allergy treatment solutions through its flagship neffy® nasal spray, supported by robust clinical development programs, strong commercial partnerships, and expanding market access across North America and Europe. The company’s financial position and strategic initiatives position it for continued growth in the biopharmaceutical allergy treatment sector.
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals Q1 Earnings Call Highlights
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
Got $300? 2 Biotech Stocks to Buy and Hold Forever